Tauriga Sciences, Inc. (OTCMKTS:TAUG) Takes Off with Late Friday Announcement
Tauriga Sciences, Inc. (OTCMKTS:TAUG) runs uneven, but still runs upward. On Friday, the ticker added more than 55% to $0.07, on buying volumes above $1.5 million. TAUG boosted its performance on Friday with updates on its foray into the medical cannabis market, specifically the plan to acquire a California-based producer of medicinal cannabis creams. 
After Honeywood, LLC becomes a wholly owned subsidiary of TAUG, it is expected that the management and previous owners would hold 32% of the TAUG common stock on a fully diluted basis. In addition to the upward of 522 million shares, TAUG may see significant dilution. We can at least hope that the new cannabis subsidiary would improve the financials that contain:
- cash: $57 thousand
- current assets: $109 thousand
- current liabilities: $1.38 million
- no revenue since inception
- quarterly net loss: $1.6 million
Investors’ forums are appreciating TAUG both for the very fast short-term gain, and for the fact that the company already has past experience with the pharmaceutical business. The news of expansion, timely and coming in at the right time, are further fueling the momentum. Still, the question is the same as for most newcomer cannabis stocks- how long will the run last before the trend deteriorates. Luckily, TAUG is for now not promoted by paid emails, which create the most disproportionate growth.
TAUG is currently in a similar situation to that of Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH), an otherwise slow-moving pharmaceutical company with some interest in stem cells, though mostly in the sphere of unrealized plans. EAPH took off for real when it announced it would enter the medical cannabis sector through a partnership with an already existing cannabis company.
The star among pharmaceutical companies that took off on the pot stock boom remains Creative Edge Nutrition, Inc. (OTCMKTS:FITX), which took off from double-zero positions. Though now FITX is stuck around the seven cent levels, it has the benefit of being a part of the Marijuana index, which ensures a stable level of investors’ interest.
In the past month, selling for TAUG has been relatively subdued, and the stock price was rarely dragged down. Pot stocks, though, tend to go through weaker weeks, as February came with a boom across the board, which had to go through a series of consolidations and corrections. A lot of newcomer tickers were ejected, others remained the go-to choice for exposure to the marijuana industry.
If you still like TAUG for its future potential, be aware that the stock is not guaranteed stability, so avoid investing unaffordable sums. So far, TAUG has shown it works well with robust PR, but activity is immediately lowered when there are quieter days.
